Covid-19 – Page 22 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2022-01-25

Two new papers reveal through cryo-EM analysis the structural basis of antibody evasion and enhanced transmission of the Omicron variant

In a study recently published on Cell, researchers used cryogenic electron microscopy (cryo-EM) analysis to capture the open and closed states of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant’s spike protein. The open and closed states of the Omicron spike appeared more compact compared to that of the SARS-CoV-2 G614 strain, which is likely due to

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-25

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae: a new paper published on Cell

A significant portion of people who contract the SARS-CoV-2 virus—some estimates suggest more than 40 percent—suffer chronic effects known as Post Acute Sequelae of COVID-19 (PASC), commonly referred to as long COVID. PASC symptoms include fatigue, brain fog, the loss of taste and smell, shortness of breath, and more. Now, researchers have identified several factors

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-21

50-64 age unvaccinated people were 44 more times to be hospitalized with COVID-19 than those who were fully vaccinated and had a booster shot, CDC shows

The risk of hospitalization for COVID-19 among older Americans is far higher for those who are unvaccinated than for those who are fully vaccinated and have had a booster shot, new government data shows. The differences were stark: In December, unvaccinated people 50 and older were 17 times more likely to be hospitalized with COVID-19 than those

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-21

New EMA report on International regulators’ recommendations on COVID-19 vaccines and the Omicron variant

International regulators have published a report today highlighting their discussions on the effectiveness of current vaccines against the COVID-19 Omicron variant, regulatory requirements for a variant vaccine and considerations on clinical study design. The workshop on the global response to the COVID-19 Omicron variant was organised under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA) and

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-20

Antibodies in blood soon after COVID-19 onset may predict severity

A look at antibodies in patients soon after they were infected with the virus that causes COVID-19 showed key differences between those whose cases remained mild and those who later developed severe symptoms. Blood drawn from patients shortly after they were infected with SARS-CoV-2, the virus that causes COVID-19, may indicate who is most likely

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-20

‘Decoy’ protein works against multiple SARS-CoV-2 variants

A drug treatment that acts as a decoy against SARS-CoV-2 was highly effective at preventing death and lung damage in humanized animal models of severe COVID-19 disease, according to a Nature Chemical Biology study from researchers at the University of Illinois Chicago. The study suggests that the drug has the potential to treat COVID-19 patients,

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-20

Fact against myth on the Omicron Variant: a WHO new information resource

Since the B.1.1.529 variant was declared a Variant of Concern and assigned the name Omicron on 26 November 2021, our understanding of this variant has increased considerably, thanks to collaborative global research and the passing of time, allowing us to observe its behaviour and how it affects individuals and communities over a number of weeks.

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-19

Covid-19 rapid antigen testing in Omicron era

Anecdotal reports and results from small studies on the diagnostics’ accuracy have prompted questions about the devices’ usage with the new variant, but researchers say more data are needed and emphasize the continued importance of SARS-CoV-2 testing. A short seven weeks after the World Health Organization declared Omicron a SARS-CoV-2 variant of concern, this new

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-19

Placebo Effect Accounts for More Than Two-Thirds of COVID-19 Vaccine Adverse Events, Researchers Find

One-Third of Clinical Trial Participants Who Received No Vaccine Reported Systemic Adverse Advents Like Headache and Fatigue The placebo effect is the well-known phenomenon of a person’s physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit – a sugar pill, or a syringe full of saline, for example. While the

No Comments InCovid-19

PIER MARIA FORNASARI
2022-01-19

A proteomic survival predictor for COVID-19 patients in intensive care

A single blood sample from a critically ill COVID-19 patient can be analyzed by a machine learning model which uses blood plasma proteins to predict survival, weeks before the outcome, according to a new study published this week in the open-access journal PLOS Digital Health by Florian Kurth and Markus Ralser of the Charité — Universitätsmedizin Berlin,

No Comments InCovid-19

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category Covid-19

Two new papers reveal through cryo-EM analysis the structural basis of antibody evasion and enhanced transmission of the Omicron variant

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae: a new paper published on Cell

50-64 age unvaccinated people were 44 more times to be hospitalized with COVID-19 than those who were fully vaccinated and had a booster shot, CDC shows

New EMA report on International regulators’ recommendations on COVID-19 vaccines and the Omicron variant

Antibodies in blood soon after COVID-19 onset may predict severity

‘Decoy’ protein works against multiple SARS-CoV-2 variants

Fact against myth on the Omicron Variant: a WHO new information resource

Covid-19 rapid antigen testing in Omicron era

Placebo Effect Accounts for More Than Two-Thirds of COVID-19 Vaccine Adverse Events, Researchers Find

A proteomic survival predictor for COVID-19 patients in intensive care